1 | 36-482-Hyaluronoglucosaminidase PH20 (rHuPH20) | 1件: Hyaluronidase Hyaluronidase | 3件: D04455
D04455
,
D04456
,
D06604
| - | - | 1件: 65 65 |
2 | Daratumumab co-formulated with recombinant human hyaluronidase (rHuPH20) | 3件: Daratumumab Daratumumab, Hyaluronidase, Hyaluronidase (human recombinant) | 4件: D04455
D04455
,
D04456
,
D06604
,
D10777
| 1件: CD38 CD38 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬 | 1件: 28 28 |
3 | Daratumumab coformulato con ialuronidasi umana ricombinante (rHuPH20) | 1件: Daratumumab Daratumumab | 1件: D10777
D10777
| 1件: CD38 CD38 💬 | 7件: Calcium signaling pathway Calcium signaling pathway, Hematopoietic cell lineage, Metabolic pathways, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Salivary secretion 💬 | 1件: 28 28 |
4 | Recombinant Human Hyaluronidase (rHuPH20) | 2件: Hyaluronidase Hyaluronidase, Hyaluronidase (human recombinant) | 3件: D04455
D04455
,
D04456
,
D06604
| - | - | 1件: 65 65 |
5 | Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV) | 1件: Hyaluronidase (human recombinant) Hyaluronidase (human recombinant) | - | - | - | 1件: 65 65 |
6 | RHuPH20 | - | - | - | - | 2件: 13 13, 14 |
7 | SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety) | - | - | - | - | 1件: 65 65 |
8 | SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety) | - | - | - | - | 1件: 65 65 |